The Role of Age in Adult ADHD Quality Care: A Longitudinal Analysis of Electronic Health Record Data.

Autor:	Callen EF; American Academy of Family Physicians, Leawood, KS, USA.; DARTNet Institute, Aurora, CO, USA., Clay T; American Academy of Family Physicians, Leawood, KS, USA.; DARTNet Institute, Aurora, CO, USA., Alai J; American Academy of Family Physicians, Leawood, KS, USA.; DARTNet Institute, Aurora, CO, USA., Goodman DW; Johns Hopkins School of Medicine, Baltimore, MD, USA.; SUNY Upstate Medical University, Syracuse, USA., Adler LA; NYU Grossman School of Medicine, New York, USA., Faraone SV; SUNY Upstate Medical University, Syracuse, USA.
Jazyk:	angličtina
Zdroj:	Journal of attention disorders [J Atten Disord] 2024 Mar; Vol. 28 (5), pp. 913-922. Date of Electronic Publication: 2023 Dec 29.
DOI:	10.1177/10870547231218042
Abstrakt:	Objective: Several studies have shown that Adult ADHD presents differently in younger and older adults. We sought to assess the difference in care between these two groups using previously identified quality measures (QMs). Methods: Using electronic health record data, we matched a younger group of ADHD patients to an older group. We then assessed the achievement of the QMs using probit models with and without interaction terms. Results: The majority of QMs shown an increase in achievement for both groups over time. However, significant differences in quality of care between younger and older adult ADHD patients persisted. By the end of the study period, with the exception of three QMs, younger patients achieved the QMs more. Conclusion: While, in general, the quality of care for adult ADHD increased from 2010 to 2020, there were still differences in care between younger and older adult ADHD patients. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Over the past 3 years, Dr. Callen received research support from PCORI, Merck, NIH, AAFP Foundation, Otsuka, Takeda, UnitedHealth Foundation, HRSA, GlaxoSmithKline, SAMHSA, Eli Lilly, CDC, Helmsley Foundation, and VaxCare. Over the past 3 years, Ms. Clay received research support from NIH, Otsuka, Takeda, UnitedHealth Foundation, HRSA, SAMHSA, Eli Lilly, and AAFP Foundation. Over the past 3 years, Ms. Alai received research support from PCORI, Abbott, Eli Lilly, and Otsuka. Over the past 3 years, Dr. Goodman received honoraria, consulting income, potential income, or travel expenses from Tris, Otsuka, Ironshore, Supernus, Sunovion, Noven, Shionogi, Ondosis, Medscape, HCPlive, Clinical Care Solutions, National Football League, WebMD, and the Neuroscience Education Institute. Over the past 3 years Dr. Adler is a consultant for Takeda, Otsuka, Bracket/Signant, Major League Baseball, the National Football League, and the State University of New York; receives grants from Takeda and Otsuka; and royalty payments from New York University School of Medicine for scales and training material for adult attention-deficit/hyperactivity disorders. Over the past 3 years, Mr. Shields received research support from PCORI, Merck, Humana, NIH, and AAFP Foundation. Over the past 3 years, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Aardvark, Aardwolf, AIMH, Tris, Otsuka, Ironshore, Kanjo, Johnson & Johnson/Kenvue, KemPharm/Corium, Akili, Supernus, Atentiv, Noven, Sky Therapeutics, Axsome, Genomind, Shire/Takeda, Arbor, Medice, Ondosis, Rhodes, and Vallon. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health; Oxford University Press: Schizophrenia: The Facts; and Elsevier: ADHD: Non-Pharmacologic Interventions. He is Program Director of www.ADHDEvidence.org and www.ADHDinAdults.com. Dr. Faraone is supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381; NIMH grants U01AR076092-01A1, 1R21MH1264940, R01MH116037; 1R01NS128535—01; Oregon Health and Science University, Otsuka Pharmaceuticals, Noven Pharmaceuticals Incorporated, and Supernus Pharmaceutical Company.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu